AFYX touts trial of biodegradable drug delivery patch

AFYX Therapeutics today touted results from a study exploring the delivery of antibody fragments using the company’s Rivelin technology.

The preclinical study, conducted in collaboration with the University of Sheffield in the United Kingdom, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue in mucosal diseases.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

AFYX Therapeutics touts study results for biodegradable oral adhesive patch

AFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch.

The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful transmucosal delivery of the corticosteroid using electrospun patch technology, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0